Q3 EPS Forecast for TuHURA Biosciences Decreased by Analyst

TuHURA Biosciences, Inc. (NASDAQ:HURA) – Investment analysts at HC Wainwright decreased their Q3 2026 earnings per share estimates for shares of TuHURA Biosciences in a report released on Wednesday, August 19th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.14) per share for the quarter, down from their previous estimate of ($0.13). The consensus estimate for TuHURA Biosciences’ current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for TuHURA Biosciences’ Q4 2026 earnings at ($0.15) EPS and FY2026 earnings at ($0.55) EPS.

TuHURA Biosciences (NASDAQ:HURA) last announced its earnings results on Friday, August 14th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01.

HURA has been the topic of several other research reports. Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Friday, July 17th. Citigroup started coverage on shares of TuHURA Biosciences in a report on Monday, April 27th. They issued an “outperform” rating for the company. Wall Street Zen downgraded shares of TuHURA Biosciences from a “hold” rating to a “sell” rating in a report on Sunday, May 31st. Finally, Citizens Jmp reaffirmed a “market outperform” rating and set a $9.00 price objective on shares of TuHURA Biosciences in a research report on Tuesday. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $9.00.

TuHURA Biosciences Stock Down 2.6%

Shares of HURA stock opened at $2.22 on Friday. TuHURA Biosciences has a 12 month low of $0.41 and a 12 month high of $3.43. The firm has a market cap of $141.48 million, a PE ratio of -4.11 and a beta of -0.01. The stock has a 50 day moving average of $2.29 and a 200-day moving average of $2.06. The company has a quick ratio of 1.15, a current ratio of 0.18 and a debt-to-equity ratio of 0.20.

Hedge Funds Weigh In On TuHURA Biosciences

A number of hedge funds have recently modified their holdings of HURA. Bank of America Corp DE bought a new position in shares of TuHURA Biosciences during the 4th quarter worth approximately $59,000. Jane Street Group LLC bought a new stake in TuHURA Biosciences in the first quarter valued at $69,000. Geode Capital Management LLC raised its stake in TuHURA Biosciences by 111.4% during the second quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock worth $1,300,000 after acquiring an additional 307,260 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in TuHURA Biosciences during the second quarter worth $27,000. Finally, New York State Common Retirement Fund bought a new position in shares of TuHURA Biosciences during the second quarter valued at $97,000. 0.62% of the stock is owned by institutional investors and hedge funds.

Key TuHURA Biosciences News

Here are the key news stories impacting TuHURA Biosciences this week:

• Positive Sentiment: Citizens JMP initiated coverage with a “Market Outperform” rating, indicating the firm sees potential for HURA to outperform the broader market. TuHURA Biosciences Earns Market Outperform Rating from Citizens JMP
• Neutral Sentiment: HC Wainwright projected a 2027 loss of approximately $0.15 to $0.16 per share per quarter, with a full-year loss estimate of $0.61 per share. These forecasts provide updated expectations but indicate that profitability is not expected in the near term.
• Negative Sentiment: HC Wainwright reduced its 2026 EPS estimates, lowering the expected third-quarter loss to $0.14 per share from $0.13, the fourth-quarter loss to $0.15 from $0.13, and the full-year loss to $0.55 from $0.50. The revisions suggest somewhat weaker near-term earnings prospects and are likely weighing on HURA shares.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.